Chronic Urticaria Clinical Trial
Official title:
Quality of Life,Anxity,Depression and Quality of Sleep in Patients With Chronic Urticaria
Verified date | May 2017 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Urticaria is one of the most frequent presenting complaints in dermatology, allergy, and emergency departments. The term chronic urticaria (CU) is understood as the appearance of recurrent wheals more than twice a week for over 6 consecutive weeks .Urticaria is not a single disease but a reaction pattern that represents cutaneous mast cell degranulation, resulting in extravasation of plasma into the dermis. The incidence of chronic urticaria is unknown, but it is thought to occur in 0.1%-3% of the population
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | August 1, 2018 |
Est. primary completion date | June 10, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: Patients with chronic urticaria defined as a 6-week or longer history of daily or almost daily itchy cutaneous weals with individual lesions lasting less than 24 h. Age between 18 and 60 years. Exclusion Criteria: Patients who are unable to understand the questions, are unwilling to complete the questionnaire, or who have a psychiatric disorder, or obstructive sleep apnea. Patients with malignant or central nervous system disease. Patients with cognitive impairment due to a current cerebral or psychotic illness. Patients with current psychotherapy . glucocorticoids therapy in the last month. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | measure number of patients affected with depression and anxity | The levels of depression and anxiety will be assessed by Hospital Anxiety Depression Scale (HADS) . | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02435238 -
AWARE - Chronic Urticaria
|
N/A | |
Not yet recruiting |
NCT05513079 -
Positive Psychotherapy-Based Counseling (PPT)
|
N/A | |
Terminated |
NCT02047136 -
Dietary Treatment for Chronic Urticaria
|
N/A | |
Completed |
NCT01803763 -
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01170949 -
Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria
|
Phase 2 | |
Completed |
NCT00598611 -
Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)
|
Phase 3 | |
Completed |
NCT01610128 -
Development of an Urticaria Control Test
|
N/A | |
Completed |
NCT02285049 -
Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test
|
N/A | |
Completed |
NCT02285023 -
The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
|
||
Completed |
NCT01715740 -
Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria
|
Phase 3 | |
Completed |
NCT01960283 -
Methotrexate in the Treatment of Chronic Idiopathic Urticaria
|
Phase 3 | |
Completed |
NCT00481676 -
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
|
Phase 2 | |
Completed |
NCT01713725 -
Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
|
Phase 2 | |
Completed |
NCT01250652 -
Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses
|
Phase 4 | |
Completed |
NCT01111136 -
Stress Intervention for Chronic Urticaria
|
N/A | |
Recruiting |
NCT01425593 -
T Cell Function in Chronic Idiopathic Urticaria
|
N/A | |
Completed |
NCT00737451 -
Association of Thyroid Autoimmunity and Chronic Urticaria
|
N/A | |
Completed |
NCT00619801 -
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
|
Phase 3 | |
Completed |
NCT00628108 -
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
|
Phase 3 | |
Completed |
NCT01284426 -
Natural History of Chronic Urticaria
|
N/A |